Welcome to our dedicated page for Enveric Biosciences SEC filings (Ticker: ENVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enveric Biosciences filings document a biotechnology issuer focused on neuroplastogenic small-molecule drug candidates for psychiatric and neurological disorders. Its periodic and current reports address operating results, pipeline updates for EB-003 and related molecule series, intellectual-property matters, risk factors and the use of investor presentation materials in Regulation FD disclosures.
The company’s SEC record also covers capital-structure and governance matters, including registered direct and private placement financings, at-the-market offering registration, common stock, pre-funded warrants, Series G, H, I and J warrants, resale registration obligations, and Nasdaq-listed common stock. Proxy materials describe director elections, executive-compensation votes, auditor ratification, reverse stock split proposals and authorized-share proposals.
Enveric Biosciences, Inc. is a pre-revenue biotechnology company developing next-generation, small-molecule neuroplastogenic therapeutics, led by EB-003 in the EVM301 Series for psychiatric and neurological disorders. EB-003 advanced through IND-enabling preclinical work, including positive phototoxicity analysis and initiation of GLP-compliant genotoxicity studies.
For the six months ended June 30, 2026, the company reported a net loss of $4,661,206 and total operating expenses of $4,660,611, with no revenue. Cash was $8,296,296 and working capital $7,931,850, bolstered by $8,348,207 of net financing cash inflows from private placements, ATM sales, and warrant exercises, raising shareholders’ equity to $8,082,524.
Management states there is substantial doubt about the ability to continue as a going concern over the next year without additional capital. Internal controls over financial reporting remain ineffective due to previously identified material weaknesses. As of August 12, 2026, 4,475,884 common shares were outstanding.
Enveric Biosciences reported second quarter 2026 results and a business update focused on its lead neuroplastogenic candidate EB-003. The company continued IND-enabling studies, reported additional preclinical data supporting a potential non-hallucinogenic profile, and initiated genotoxicity studies needed for an Investigational New Drug application and a planned Phase 1 trial.
Enveric also expanded its intellectual property, securing a new U.S. patent covering methods of treating psychiatric disorders with EVM301 Series compounds and receiving a Notice of Allowance for a patent on its EVM401 Series of methylone-inspired neuroplastogens. Financially, net loss attributable to stockholders was $3.0 million for the quarter ended June 30, 2026, or $0.76 per basic and diluted share, compared with a net loss of $2.5 million and $11.65 per share a year earlier. Cash-on-hand was $8.3 million as of June 30, 2026, supported by $5.0 million in gross offering proceeds and $1.5 million from warrant exercises during the quarter.
Enveric Biosciences, Inc. received an updated Schedule 13G/A from Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton reporting their beneficial ownership through Series G Warrants to purchase common stock. Each reporting person now reports beneficial ownership of 1.3%–1.4% of Enveric's common stock, all below 5% of the class.
The filing notes that 49,366–51,866 Series G Warrants are held across the reporting persons, with sole voting and dispositive power and no shared power reported. The Series G Warrants include a 9.99% beneficial ownership limitation, restricting conversions that would result in ownership above that threshold.
Armistice Capital, LLC and Steven Boyd report a significant holding in Enveric Biosciences, Inc. common stock. They report beneficial ownership of 405,092 shares of common stock, representing 9.99% of the class.
Armistice Capital, a Delaware investment adviser, has shared voting and dispositive power over 405,092 shares and no sole voting or dispositive power. Steven Boyd, a U.S. citizen and managing member of Armistice Capital, may also be deemed to beneficially own these securities. The shares are directly held by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager under an Investment Management Agreement. The Master Fund has the right to receive dividends and sale proceeds from these securities.
ENVERIC BIOSCIENCES, INC. has an updated Schedule 13G/A reporting that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri collectively report beneficial ownership of 111,145 shares of common stock through warrants. These shares are issuable upon exercise of certain warrants that are subject to a 9.99% beneficial ownership blocker, limiting how many shares can be acquired at any time. Based on 3,681,884 common shares outstanding as of May 13, 2026, plus the 111,145 issuable warrant shares, each reporting person reports beneficial ownership of 2.93% of the common stock as of June 30, 2026, with sole voting and dispositive power over the reported shares.
Enveric Biosciences, Inc. filed an 8-K to report that on June 9, 2026 it filed a prospectus supplement to offer an additional $2,425,000 of shares of its common stock under its existing at-the-market equity offering program with H.C. Wainwright & Co., LLC as sales agent. Prior to this date, the company had sold an aggregate of $4,483,711.04 through the sales agent under the same agreement. A legal opinion from Greenberg Traurig, LLP regarding the validity of the shares is included as an exhibit.
Enveric Biosciences files a prospectus supplement updating an at-the-market (ATM) facility to offer up to $2,425,000 aggregate offering price of Common Stock pursuant to an ATM Agreement with H.C. Wainwright & Co., LLC.
The supplement states Enveric has previously sold $3,199,400.98 of Common Stock under the ATM Agreement and sold $4,483,711.04 of securities under General Instruction I.B.6 of Form S-3 in the prior 12 months. The one-third limitation under General Instruction I.B.6 applies based on non-affiliate market value, and the supplement ties the updated offering limit to that rule.
Enveric Biosciences, Inc. furnished a Q2 2026 investor presentation under Regulation FD. The company plans to post this Investor Presentation on its website and use it in discussions with current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, and employees.
The Investor Presentation is attached as Exhibit 99.1 and is also accessible via the company’s investor events webpage. The information in this report, including Exhibit 99.1, is furnished rather than filed under the Exchange Act, limiting its treatment under Section 18 and other incorporation-by-reference provisions.
Coveney Kevin Michael reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences, Inc. reported that Chief Financial Officer Kevin Michael Coveney received a grant of 133,333 restricted stock units under the company’s 2020 Long-Term Incentive Plan. These RSUs are a form of equity compensation and were granted at no cash cost per unit.
For each vested RSU, Coveney will receive one share of common stock, bringing his total reported direct holdings to 180,746 shares after the grant. One-fourth of the RSUs will vest on the one-year anniversary of the grant date, then one‑thirty‑sixth will vest each month, with any remaining RSUs vesting on the fourth anniversary, all conditioned on continued employment.
Enveric Biosciences, Inc. CEO Joseph Edward Tucker received a grant of 201,124 restricted stock units of common stock under the company’s 2020 Long-Term Incentive Plan. These RSUs have no cash exercise price; one share of common stock will be issued for each vested unit. One-fourth of the RSUs will vest on the one-year anniversary of the grant date, with an additional one‑thirty‑sixth vesting each month thereafter, and any remaining RSUs vesting on the fourth anniversary, subject to continued employment. Following this award, Tucker directly holds 271,479 shares of common stock.